Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Hristos Polymeropoulos Sells 72,872 Shares

Share on StockTwits

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos sold 72,872 shares of the firm’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $15.34, for a total value of $1,117,856.48. Following the completion of the transaction, the chief executive officer now owns 1,276,343 shares of the company’s stock, valued at approximately $19,579,101.62. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Mihael Hristos Polymeropoulos also recently made the following trade(s):

  • On Friday, May 17th, Mihael Hristos Polymeropoulos sold 77,225 shares of Vanda Pharmaceuticals stock. The stock was sold at an average price of $15.56, for a total value of $1,201,621.00.
  • On Monday, March 4th, Mihael Hristos Polymeropoulos sold 38,166 shares of Vanda Pharmaceuticals stock. The stock was sold at an average price of $19.41, for a total value of $740,802.06.
  • On Friday, March 1st, Mihael Hristos Polymeropoulos sold 6,500 shares of Vanda Pharmaceuticals stock. The stock was sold at an average price of $20.22, for a total value of $131,430.00.

VNDA traded up $1.48 during midday trading on Tuesday, hitting $16.39. 746,467 shares of the company were exchanged, compared to its average volume of 834,370. The company has a market capitalization of $789.69 million, a P/E ratio of 34.15 and a beta of 0.44. Vanda Pharmaceuticals Inc. has a 1-year low of $13.66 and a 1-year high of $33.44.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.08). The company had revenue of $47.71 million for the quarter, compared to analyst estimates of $51.74 million. Vanda Pharmaceuticals had a return on equity of 8.07% and a net margin of 10.92%. Vanda Pharmaceuticals’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.14 earnings per share. As a group, analysts predict that Vanda Pharmaceuticals Inc. will post 0.06 earnings per share for the current fiscal year.

A number of equities analysts recently issued reports on the company. Zacks Investment Research lowered Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. Oppenheimer set a $18.00 price target on Vanda Pharmaceuticals and gave the stock a “hold” rating in a research report on Sunday, May 5th. Citigroup downgraded Vanda Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Thursday, May 2nd. ValuEngine downgraded Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 18th. Finally, BidaskClub downgraded Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, April 11th. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the stock. Vanda Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $33.63.

A number of institutional investors and hedge funds have recently made changes to their positions in VNDA. Comerica Bank lifted its stake in Vanda Pharmaceuticals by 1.4% in the first quarter. Comerica Bank now owns 51,842 shares of the biopharmaceutical company’s stock valued at $928,000 after acquiring an additional 725 shares during the last quarter. Piedmont Investment Advisors Inc. raised its position in shares of Vanda Pharmaceuticals by 5.9% during the 1st quarter. Piedmont Investment Advisors Inc. now owns 13,198 shares of the biopharmaceutical company’s stock valued at $243,000 after buying an additional 737 shares during the period. Advisor Group Inc. raised its position in shares of Vanda Pharmaceuticals by 27.3% during the 1st quarter. Advisor Group Inc. now owns 3,712 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 796 shares during the period. Thrivent Financial for Lutherans raised its position in shares of Vanda Pharmaceuticals by 2.2% during the 4th quarter. Thrivent Financial for Lutherans now owns 37,074 shares of the biopharmaceutical company’s stock valued at $969,000 after buying an additional 815 shares during the period. Finally, Rhumbline Advisers raised its position in shares of Vanda Pharmaceuticals by 0.6% during the 1st quarter. Rhumbline Advisers now owns 149,949 shares of the biopharmaceutical company’s stock valued at $2,759,000 after buying an additional 832 shares during the period. 98.58% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Hristos Polymeropoulos Sells 72,872 Shares” was originally posted by Highlight Press and is the property of of Highlight Press. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://highlightpress.com/2019/05/21/vanda-pharmaceuticals-inc-vnda-ceo-mihael-hristos-polymeropoulos-sells-72872-shares.html.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Featured Article: Overbought

Insider Buying and Selling by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.